Gail V. W. Johnson

Dr. Gail V. W. Johnson

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2008 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
HDHuiping Ding
Huiping Ding
PDPhilip J. Dolan
Philip J. Dolan
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson
Histone deacetylase 6 (HDAC6), a unique cytoplasmic deacetylase, likely plays a role in neurodegeneration by coordinating cell responses to abnormal protein aggregation. Here, we provide in vitro and in vivo evidence that HDAC6 interacts with tau, a microtubule‐associated protein that forms neurofibrillary tangles in Alzheimer’s disease. This interaction is mediated by the microtubule‐binding domain on tau and the Ser/Glu tetradecapeptide domain on HDAC6. Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6–tau interaction. Nonetheless tubacin treatment attenuated site‐specific tau phosphorylation, as did shRNA‐mediated knockdown of HDAC6. Proteasome inhibition potentiated HDAC6–tau interactions and facilitated the concentration and co‐localization of HDAC6 and tau in a perinuclear aggresome‐like compartment, independent of HDAC6 tubulin deacetylase activity. Furthermore, we observed that in Alzheimer’s disease brains the protein level of HDAC6 was significantly increased. These findings establish HDAC6 as a tau‐interacting protein and as a potential modulator of tau phosphorylation and accumulation.

25 March 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
CJChulman Jo
Chulman Jo
SGSoner Gundemir
Soner Gundemir
SPSusanne Pritchard
Susanne Pritchard
YJYoungnam N. Jin
Youngnam N. Jin
IRIrfan Rahman
Irfan Rahman
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a pivotal transcription factor in the defence against oxidative stress. Here we provide evidence that activation of the Nrf2 pathway reduces the levels of phosphorylated tau by induction of an autophagy adaptor protein NDP52 (also known as CALCOCO2) in neurons. The expression of NDP52, which we show has three antioxidant response elements (AREs) in its promoter region, is strongly induced by Nrf2, and its overexpression facilitates clearance of phosphorylated tau in the presence of an autophagy stimulator. In Nrf2-knockout mice, phosphorylated and sarkosyl-insoluble tau accumulates in the brains concurrent with decreased levels of NDP52. Moreover, NDP52 associates with phosphorylated tau from brain cortical samples of Alzheimer disease cases, and the amount of phosphorylated tau in sarkosyl-insoluble fractions is inversely proportional to that of NDP52. These results suggest that NDP52 plays a key role in autophagy-mediated degradation of phosphorylated tau in vivo.

1 February 2012 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
SGSoner Gundemir
Soner Gundemir
GCGozde Colak
Gozde Colak
JTJanusz Tucholski
Janusz Tucholski
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson

1 January 2013 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
ACAdrianne S. Chesser
Adrianne S. Chesser
SPSusanne M. Pritchard
Susanne M. Pritchard
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson
One of the defining pathological features of Alzheimer disease (AD) is the intraneuronal accumulation of tau. Tau that forms these accumulations is altered both posttranslationally and conformationally, and there is now significant evidence that soluble forms of these modified tau species are the toxic entities rather than the insoluble neurofibrillary tangles (NFTs). However there is still noteworthy debate concerning which specific pathological forms of tau are the contributors to the neuronal dysfunction and death in AD. Nonetheless, given that increases in aberrant forms of tau play a role in the neurodegeneration process in AD, there is growing interest in understanding the degradative pathways that remove tau from the cell, and the selectivity of these different pathways for these various forms of tau. Indeed, one can speculate that deficits in a pathway that selectively removes certain pathological forms of tau could play a pivotal role in AD. In this review we will discuss the different proteolytic and degradative machineries that may be involved in removing tau from the cell. How deficits in these different degradative pathways may contribute to abnormal accumulation of tau in AD will also be considered. In addition, the issue of the selective targeting of specific tau species to a given degradative pathway for clearance from the cell will be addressed.

1 April 2019 in Progress in Neurobiology
Verified
Journal Article
Closed access
CTCheril Tapia-Rojas
Cheril Tapia-Rojas
FCFabian Cabezas-Opazo
Fabian Cabezas-Opazo
CDCarol A. Deaton
Carol A. Deaton
EVErick H. Vergara
Erick H. Vergara
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson
Rodrigo A. QuintanillaRodrigo A. Quintanilla
Rodrigo A. Quintanilla

1 October 2009 in Brain Research Bulletin
Verified
Journal Article
Closed access
RQRodrigo A. Quintanilla
Rodrigo A. Quintanilla
Gail V. W. JohnsonGail V. W. Johnson
Gail V. W. Johnson